Evidence map›Paper›PMID 41816837›Full record

ReviewHaematologica2026

Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.

Vivian G Oehler, Ellin Berman, Ivan J Huang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vivian G OehlerTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA. voehler@fredhutch.org.
Ellin BermanLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Ivan J HuangHematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Pharmacy, University of Washington Medical Center, Seattle, WA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Targeted therapies have made a near-normal lifespan an attainable goal for many patients with chronic phase chronic myeloid leukemia. Most patients require years of therapy and not everyone may be able to discontinue treatment permanently without recurrence of the leukemia. BCR::ABL1 targeted tyrosine kinase inhibitors, including ATP binding site and allosteric inhibitors that bind to the myristoyl pocket, are associated with treatment-emergent adverse events that may compromise quality of life and well-being. Although alternative treatment options exist, side effects may persist, or new ones occur after a therapy switch. Using a case-based approach, this review examines the incidence of non-hematologic and hematologic treatment-emergent adverse events with specific therapies, provides guidance on adverse event management, and describes the impact of therapy dose reduction on efficacy and tolerability.

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsDisease ManagementFusion Proteins, bcr-ablHumansProtein-Tyrosine KinasesAntineoplastic AgentsFusion Proteins, bcr-ablProtein Kinase InhibitorsProtein-Tyrosine Kinases

Identifiers

PMID41816837
PMCPMC13317837

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.